With FDA nod, Philips adds cardiac imaging to smartphone plug-in ultrasound device

Lumify--Courtesy of Philips

The FDA cleared Philips’ cardiac transducer for use with Lumify, the company’s smart-device diagnostic ultrasound. The new add-on brings cardiac imaging to the portable diagnostic, which already allows doctors to scan the gallbladder and lungs among other areas.

Launched a year ago, the Lumify package consists of an app and two transducers for use with an Android smartphone, as well as access to an online portal and Philips support. The app connects to the cloud, where clinicians may access data and images through Philips’ HealthSuite Digital Platform. In addition to cardiac and abdominal scanning, Lumify also offers OB/GYN and focused assessment with sonography for trauma (FAST) examinations.

"Our vision for smart-device ultrasounds is focused on putting high-quality devices in the hands of more professionals to serve more patients in more locations," said Randy Hamlin, vice president and point-of-care business leader for Philips Ultrasound, in a statement. "With the S4-1 transducer and clinical pre-sets, Lumify is further extending the reach of ultrasound by delivering exceptional image quality, now for routine cardiac exams, and creating better connections between clinicians and their patients."

Event

Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

The new S4-1 cardiac transducer weighs less than a smartphone and joins the existing two transducers for use in emergency care, critical care and ambulances, according to the statement. Lumify's low cost and portability allows doctors in emergency situations to quickly triage patients without needing to locate and procure an ultrasound cart, Philips said in the statement.

Lumify was launched on a $199 monthly subscription model, securing an ongoing income stream for Philips. Now, it is also available as a one-time purchase.

Read more on

Suggested Articles

Ironwood had once hyped this drug as a $2 billion-a-year asset, but IW-3718 has failed to live up to its high expectations.

The company describes the continuous glucose monitor as the world’s smallest and thinnest diabetes sensor, with a disc about the size of two pennies.

Junshi’s PD-1 blocker is already approved in China for metastatic melanoma, but the Shanghai-based biotech may soon add throat cancer to its label.